Cooper Companies (The) vs Labcorp

Side-by-side comparison of AI visibility scores, market position, and capabilities

AI visibility is closely matched (75 vs 79)
Cooper Companies (The) logo

Cooper Companies (The)

LeaderHealthcare Tech

Enterprise

San Ramon CA contact lenses and fertility devices (NASDAQ: COO) $3.87B FY2024 revenue (+9%); CooperVision MiSight myopia management, CooperSurgical IVF consumables, competing with J&J Vision and Alcon.

AI VisibilityBeta
Overall Score
B75
Category Rank
#77 of 596
AI Consensus
80%
Trend
stable
Per Platform
ChatGPT
79
Perplexity
78
Gemini
74

About

The Cooper Companies, Inc. is a San Ramon, California-based medical device company — publicly traded on the NASDAQ (NASDAQ: COO) as an S&P 500 Health Care component — operating two segments: CooperVision (soft contact lenses for vision correction globally — the second-largest contact lens manufacturer worldwide) and CooperSurgical (fertility and women's health medical devices including IVF laboratory consumables, assisted reproductive technology products, and gynecological surgical instruments) through approximately 15,000 employees in 130 countries. In fiscal year 2024 (ending October 2024), Cooper Companies reported revenues of $3.87 billion (+9% organic growth), with CooperVision generating $2.56 billion from daily, biweekly, and monthly contact lens sales across sphere, toric (astigmatism-correcting), and multifocal (presbyopia-correcting) lens categories, and CooperSurgical generating $1.31 billion from fertility clinic consumables and women's health surgical products. CEO Albert White has executed CooperVision's strategy of capturing the premium daily silicone hydrogel lens market: silicone hydrogel material (higher oxygen permeability improving eye health versus conventional hydrogel) commands a 20-30% price premium over conventional daily lenses, and Cooper's MyDay (premium daily silicone hydrogel) and clariti (value silicone hydrogel) brands compete across price tiers against Johnson & Johnson Vision's Acuvue Oasys and CIBA Vision's AIR OPTIX brands for the global market shift toward dailies — the fastest-growing contact lens modality as patients prefer the convenience and hygiene of discarding lenses after each day's wear.

Full profile
Labcorp logo

Labcorp

LeaderHealthcare Tech

Enterprise

Burlington NC clinical laboratory services (NYSE: LH) ~$13.1B FY2024 revenue; Fortrea CRO spun off 2023, 2000+ PSC network, specialty oncology molecular testing competing with Quest Diagnostics.

AI VisibilityBeta
Overall Score
B79
Category Rank
#31 of 596
AI Consensus
68%
Trend
up
Per Platform
ChatGPT
74
Perplexity
82
Gemini
73

About

Laboratory Corporation of America Holdings (Labcorp) is a Burlington, North Carolina-based clinical laboratory and life sciences company — publicly traded on the New York Stock Exchange (NYSE: LH) as an S&P 500 Health Care component — providing diagnostic laboratory testing services for physicians, hospitals, health systems, and patients across the United States and internationally, and providing drug development laboratory services (biopharmaceutical clinical trial laboratory support) through approximately 60,000 employees. In fiscal year 2024, Labcorp reported revenues of approximately $13.1 billion from the Diagnostics segment — following the June 2023 separation of its Drug Development segment as Fortrea Holdings (NASDAQ: FTRE), an independent public company providing CRO (contract research organization) services to pharmaceutical and biotech clients. CEO Adam Schechter has focused the post-Fortrea Labcorp on the pure-play diagnostics business: clinical testing across 6,000+ test menu items (routine blood work, specialty genetic testing, toxicology, and anatomic pathology) processed at Labcorp's 2,000+ patient service centers and sent to regional and specialty reference laboratories for results reporting to ordering physicians. The Labcorp consumer-direct testing initiative (at-home specimen collection kits for STI testing, COVID testing, and other direct-to-consumer tests ordered at labcorp.com without physician referral) expands beyond the traditional physician-ordered testing model to capture the growing consumer health testing market. Labcorp's specialty testing portfolio (oncology genomic profiling, rare disease genetic panels, prenatal cell-free DNA testing, advanced cardiac biomarker panels) generates higher revenue per requisition than routine chemistry and hematology panels — driving mix shift toward specialty and molecular testing revenue.

Full profile

AI Visibility Head-to-Head

75
Overall Score
79
#77
Category Rank
#31
80
AI Consensus
68
stable
Trend
up
79
ChatGPT
74
78
Perplexity
82
74
Gemini
73
77
Claude
85
71
Grok
75

Key Details

Category
Enterprise
Enterprise
Tier
Leader
Leader
Entity Type
company
company

Capabilities & Ecosystem

Integrations

Both integrate with
Only Cooper Companies (The)
Only Labcorp
Cooper Companies (The) is classified as company. Labcorp is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.